NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update
Remains on Track to Initiate an Expansion Study of NUC-7738 in Combination with Pembrolizumab for Patients with PD-1 Inhibitor-Resistant Melanoma ...